Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting-Reference-Cited by-同舟云学术

Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting

Published:2014-12 Issue:12 Volume:36 Page:2015-2028.e2
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Zheng Ying,Sorensen Sonja V.,Gonschior Ann-Katrin,Noack Herbert,Heinrich-Nols Jutta,Sunderland Tom,Kansal Anuraag R.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference45 articles.

1. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study;Heeringa;Eur Heart J,2006

2. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated;Gladstone;Stroke,2009

3. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study;Marini;Stroke,2005

4. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition);Ansell;Chest,2008

5. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?;Gallagher;J Thromb Haemost,2008

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review;Applied Health Economics and Health Policy;2023-10-29

2. Cost-Effectiveness of Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation in Hong Kong;Value in Health Regional Issues;2023-07

3. Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review;PharmacoEconomics;2023-05-19

4. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis;BMJ Evidence-Based Medicine;2021-10-11

5. Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study;Cardiovascular Diabetology;2020-10-10